Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies.

Next Previous
Trial Profile

Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Sodium metaarsenite (Primary)
  • Indications Cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacogenomic

Most Recent Events

  • 13 Mar 2020 Status changed from completed to discontinued.
  • 01 Nov 2016 Status changed from recruiting to completed as per results published in the Cancer Chemotherapy and Pharmacology.
  • 01 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top